Granulocyte-macrophage colony-stimulating factor as infection prophylaxis in high-risk oncologic surgery

American Journal of Surgery

Volumn 172, Issue 3, 1996, Pages 299-302

  Meropol, Neal J ^a   Petrelli, Nicholas J ^a   Lipman, Brian J ^a   Rodriguez Bigas, Miguel ^a   Hicks, Wesley ^a   Douglass Jr , Harold O ^a   Smith, Judy L ^a   Rasey, Maryanne ^a   Blumenson, Leslie E ^a   Vaickus, Louis ^a   Hayes, F Ann ^b   Agosti, Jan M ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; LEUKOCYTE COUNT; MALE; NEUTROPHIL; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; WOUND INFECTION;

EID: 0030248692     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(96)00106-7     Document Type: Article

References (11)

1. 1. Galandiuk S, Polk HC, Jr, Jagelman DG, Fazio VW. Re-emphasis of priorities in surgical antibiotic prophylaxis. Surg Gynecol Obstet. 1989;169:219-222.
2. 2. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (first of two parts). NEJM. 1992;327:28-35.
3. 3. Antman KS, Griffin JD, Elias A, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. NEJM. 1988;319:593-598.
4. 4. Burgess AW, Begley CG, Johnson GR, et al. Purification and properties of bacterially synthesized human granulocyte-macrophage colony stimulating factor. Blood. 1987;69:43-51.
5. 5. Kaplan SS, Basford RE, Wing EJ, Shadduck RK. The effect of recombinant human granulocyte macrophage colony-stimulating factor on neutrophil activation in patients with refractory carcinoma. Blood. 73;636:638.
6. 6. Mandell GL, Douglas RG, Bennett JE. In: Principles and Practice of Infectious Diseases: Antimicrobial Therapy. New York: Churchill and Livingstone, 1992:95-107.
7. 7. Wing EJ, Magee DM, Whiteside TL, et al. Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor a and interferon in cancer patients. Blood. 1989;73:643-646.
8. 8. Thomassen MJ, Ahmad M, Barna BP, et al. Induction of cytokine messenger RNA and secretion in alveolar macrophages and blood monocytes from patients with lung cancer receiving granulocyte-macrophage colony-stimulating factor therapy. Cancer Res. 1991;51:857-862.
9. 9. Freischlag J, Busuttil RW. The value of postoperative fever evaluation. Surgery. 1983;94:358-363.
10. 10. Weigelt JA, Fever hypothermia, and delerium. In: Current Practice of Surgery, Vol 1. Levine BA, Copeland EM, Howard RJ, Sugarman HJ, Warshaw AL, eds. New York: Chuchill Livingstone, 1993:5:3-5:5.
11. 11. Lieschke GJ, Maher D, Cebon J, et al. Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. Ann Intern Med. 1989;110:357-364.